← Back to All US Stocks

Prestige Consumer Healthcare Inc. (PBH) Fundamental Analysis & AI Grade 2026

PBH NYSE Pharmaceutical Preparations CIK: 0001295947
Updated This Month • Analysis: May 15, 2026 • SEC Data: 2026-03-31
Combined AI Grade
B
68% Confidence
N/A
B
68% Conf
Pending
Analysis scheduled

📊 PBH Key Takeaways

Revenue: $1.1B
Net Margin: 17.5%
Free Cash Flow: $246.4M
Current Ratio: 3.57x
Debt/Equity: 0.53x
EPS: $3.91
AI Grade: B with 68% confidence
Prestige Consumer Healthcare Inc. (PBH) receives a B fundamental grade with 68% confidence from our AI analysis based on SEC 10-K filings. With revenue of $1.1B, net profit margin of 17.5%, and return on equity (ROE) of 10.1%, Prestige Consumer Healthcare Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete PBH stock analysis for 2026.

Is Prestige Consumer Healthcare Inc. (PBH) a Good Investment?

Claude

Prestige Consumer Healthcare demonstrates strong operational fundamentals with 28.4% operating margins, excellent liquidity (3.57x current ratio), and robust free cash flow generation ($246.4M). However, the 2671% revenue surge coupled with 11.3% net income decline and 8.9% EPS decline signals poor acquisition quality or severe integration challenges that undermine earnings durability.

Prestige Consumer Healthcare Inc. Key Strengths (PBH)

Claude
  • + Exceptional operating margin (28.4%) and net margin (17.5%) with strong FCF generation ($246.4M, 22.6% FCF margin)
  • + Fortress-like balance sheet: 3.57x current ratio, 171.9x interest coverage, and moderate 0.53x debt/equity leverage
  • + Established pharma/OTC consumer healthcare business model with stable, recurring revenue characteristics

PBH Stock Risks: Prestige Consumer Healthcare Inc. Investment Risks

Claude
  • ! Net income declining 11.3% YoY despite extraordinary 2671% revenue growth indicates poor acquisition accretion or massive integration costs eroding profitability
  • ! EPS down 8.9% despite revenue surge reflects shareholder dilution and rising cost structure threatening earnings sustainability
  • ! Critically low cash position ($63.9M) against $994M debt creates refinancing vulnerability if operating cash flow deteriorates

Key Metrics to Watch

Claude
  • * Normalized net income and EPS trajectory post-acquisition - must show stabilization and growth to validate deal quality
  • * Operating cash flow sustainability and free cash flow generation - any decline below $200M annually signals distress
  • * Debt reduction progress and cash position growth - critical to reduce leverage given liquidity constraints

Prestige Consumer Healthcare Inc. (PBH) Financial Metrics & Key Ratios

Revenue
$1.1B
Net Income
$190.3M
EPS (Diluted)
$3.91
Free Cash Flow
$246.4M
Total Assets
$3.5B
Cash Position
$63.9M

💡 AI Analyst Insight

The 22.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.57x current ratio provides a solid financial cushion.

PBH Profit Margin, ROE & Profitability Analysis

Gross Margin 54.7%
Operating Margin 28.4%
Net Margin 17.5%
ROE 10.1%
ROA 5.4%
FCF Margin 22.6%

PBH vs Healthcare Sector: How Prestige Consumer Healthcare Inc. Compares

How Prestige Consumer Healthcare Inc. compares to Healthcare sector averages

Net Margin
PBH 17.5%
vs
Sector Avg 12.0%
PBH Sector
ROE
PBH 10.1%
vs
Sector Avg 15.0%
PBH Sector
Current Ratio
PBH 3.6x
vs
Sector Avg 2.0x
PBH Sector
Debt/Equity
PBH 0.5x
vs
Sector Avg 0.6x
PBH Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Prestige Consumer Healthcare Inc. Stock Overvalued? PBH Valuation Analysis 2026

Based on fundamental analysis, Prestige Consumer Healthcare Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
10.1%
Sector avg: 15%
Net Profit Margin
17.5%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.53x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Prestige Consumer Healthcare Inc. Balance Sheet: PBH Debt, Cash & Liquidity

Current Ratio
3.57x
Quick Ratio
2.25x
Debt/Equity
0.53x
Debt/Assets
46.0%
Interest Coverage
171.89x
Long-term Debt
$994.0M

PBH Revenue & Earnings Growth: 5-Year Financial Trend

PBH 5-year financial data: Year 2022: Revenue $1.1B, Net Income $142.3M, EPS $2.78. Year 2023: Revenue $1.1B, Net Income $164.7M, EPS $3.25. Year 2024: Revenue $1.1B, Net Income $205.4M, EPS $4.04. Year 2025: Revenue $1.1B, Net Income -$82.3M, EPS $-1.65. Year 2026: Revenue $1.1B, Net Income $209.3M, EPS $4.17.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Prestige Consumer Healthcare Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $4.17 reflects profitable operations.

PBH Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
22.6%
Free cash flow / Revenue

PBH Quarterly Earnings & Performance

Quarterly financial performance data for Prestige Consumer Healthcare Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2026 $283.4M $46.7M $0.97
Q2 2026 $274.1M $42.2M $0.86
Q1 2026 $249.5M $47.5M $0.95
Q3 2025 $282.7M $53.0M $1.06
Q2 2025 $283.8M $53.6M $1.07
Q1 2025 $267.1M $49.1M $0.98
Q3 2024 $275.5M $52.0M $1.04
Q2 2024 $286.3M $51.0M $1.02

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Prestige Consumer Healthcare Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$257.6M
Cash generated from operations
Stock Buybacks
$156.3M
Shares repurchased (TTM)
Capital Expenditures
$11.2M
Investment in assets
Dividends
None
No dividend program

PBH SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Prestige Consumer Healthcare Inc. (CIK: 0001295947)

📋 Recent SEC Filings

Date Form Document Action
May 14, 2026 10-K pbh-20260331.htm View →
May 13, 2026 8-K pbh-20260513.htm View →
May 12, 2026 4 xslF345X06/tm2614335-1_4seq1.xml View →
May 11, 2026 4 xslF345X06/tm2614203-4_4seq1.xml View →
May 11, 2026 4 xslF345X06/tm2614203-3_4seq1.xml View →

Frequently Asked Questions about PBH

What is the AI rating for PBH?

Prestige Consumer Healthcare Inc. (PBH) has an AI grade of B with 68% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PBH's key strengths?

Claude: Exceptional operating margin (28.4%) and net margin (17.5%) with strong FCF generation ($246.4M, 22.6% FCF margin). Fortress-like balance sheet: 3.57x current ratio, 171.9x interest coverage, and moderate 0.53x debt/equity leverage.

What are the risks of investing in PBH?

Claude: Net income declining 11.3% YoY despite extraordinary 2671% revenue growth indicates poor acquisition accretion or massive integration costs eroding profitability. EPS down 8.9% despite revenue surge reflects shareholder dilution and rising cost structure threatening earnings sustainability.

What is PBH's revenue and growth?

Prestige Consumer Healthcare Inc. reported revenue of $1.1B.

Does PBH pay dividends?

Prestige Consumer Healthcare Inc. does not currently pay dividends.

Where can I find PBH SEC filings?

Official SEC filings for Prestige Consumer Healthcare Inc. (CIK: 0001295947) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PBH's EPS?

Prestige Consumer Healthcare Inc. has a diluted EPS of $3.91.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is PBH's fundamental grade?

Based on our AI fundamental analysis in May 2026, Prestige Consumer Healthcare Inc. has a B grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is PBH stock overvalued or undervalued?

Valuation metrics for PBH: ROE of 10.1% (sector avg: 15%), net margin of 17.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is PBH's AI grade for 2026?

Our dual AI analysis gives Prestige Consumer Healthcare Inc. a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.

What is PBH's free cash flow?

Prestige Consumer Healthcare Inc.'s operating cash flow is $257.6M, with capital expenditures of $11.2M. FCF margin is 22.6%.

How does PBH compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 17.5% (avg: 12%), ROE 10.1% (avg: 15%), current ratio 3.57 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 15, 2026 | Data as of: 2026-03-31 | Powered by Claude AI